European CHMP recommends license extensions for cemiplimab (Libtayo) for basal cell carcinoma and non-small cell lung cancer

The proposed license extensions are as monotherapy for locally advanced or metastatic basal cell carcinoma, andas first-line treatment of locally advanced or metastatic non-small cell lung cancer expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations.

Source:

European Medicines Agency